MarketBeat
14 May 2026, 15:07 UTC · 18w ago
Verdict
Headline leans bullish. We score AXGN +0.60 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
A CMS outpatient reimbursement reclassification effective January 1, 2026, resulted in an approximately 40% rate increase for nerve procedures.
More positive than 98% of claims this week
AxoGen maintains its full-year guidance of at least 20% growth and expects continuous double-digit growth over the next three to five years.
So whatStrong growth targets provide a bullish baseline for valuation, though these are reiterated rather than new targets.
Continue reading
5 related stories
More positive than 70% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 84% of claims this week
Aetna remains the last significant payer yet to make a reimbursement decision, with a response hoped for by the end of June.
More positive than 76% of claims this week
Gross margins are expected to bottom in Q2 due to a transition to BLA product, potentially hitting the low end of the 74% to 76% annual guidance range.
More negative than 76% of claims this week
Clinical data from a prostate nerve repair pilot is expected in the second half of the year to determine if a go-to-market plan is viable.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company reports strong first-quarter growth, maintains a double-digit growth outlook, and is seeing positive reimbursement wins and CMS reclassification.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
+9.8%
Price agrees with the score
$44.23 vs $40.29 close before publication (May 13) · not market-adjusted
AXGN chart →
